Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome
| Autor: | Mineui Hong, Jeong Won Kim, Min Kyoon Kim, Soo Kyung Ahn, Bong Wha Chung |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
PD-L1 Stromal cell stromal immune cells immune-oncology 03 medical and health sciences 0302 clinical medicine Breast cancer Immune system breast cancer Growth factor receptor medicine biology business.industry medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Monoclonal Cancer research biology.protein Immunohistochemistry prognosis Antibody business Research Paper |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| Popis: | Purpose: The programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays an important role in antitumor immune responses. However, there is considerable inconsistency regarding the prognostic value of PD-L1 expression status in breast cancer. We sought to evaluate the differential prognostic impacts of tumoral versus stromal immune cell PD-L1 expression in primary breast cancer. Materials & Methods: Both tumoral and stromal immune PD-L1 expression in formalin-fixed, paraffin-embedded tumor samples from 233 breast cancer patients without initial stage IV metastases were evaluated by immunohistochemistry using a mouse monoclonal anti-PDL1 antibody. Clinicopathological variables were also documented. A Cox regression model was used to assess the association of tumoral/stromal immune PD-L1 expression with clinical outcome using disease-free survival (DFS) as the primary end point. Results: Both tumoral and stromal immune PD-L1 expression were associated with aggressive tumor characteristics, including higher histologic grade, as well as negative estrogen receptor, negative progesterone receptor, and positive human epithelial growth factor receptor 2 (HER2) status Multivariate analyses further demonstrated that stromal immune cell, but not tumoral, PD-L1 expression was a favorable prognostic factor for survival. Conclusions: Despite its association with aggressive tumor features, PD-L1 expression on stromal immune cells emerged as a positive prognostic biomarker in breast cancer. This pro-survival effect might reflect the presence of a strong antitumor immune response that leads to PD-L1 expression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|